Darunavir Is a Good Third-Line Antiretroviral Agent for HIV Type 1-Infected Patients Failing Second-Line Protease Inhibitor-Based Regimens in South India

Eleven protease mutations have been associated with reduced susceptibility to darunavir. In this study of 87 HIV-1-infected patients experiencing virological failure to second-line regimens containing protease inhibitors boosted with ritonavir (viral load >1,000 HIV RNA copies/ml), we observed a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Saravanan, Shanmugam, Madhavan, Vidya, Balakrishnan, Pachamuthu, Smith, Davey M., Solomon, Sunil Suhas, Sivamalar, Sathasivam, Poongulali, Selvamuthu, Kumarasamy, Nagalingeswaran, Schooley, Robert T., Solomon, Suniti, Kantor, Rami
Format: Artigo
Idioma:Inglês
Publicat: Mary Ann Liebert, Inc. 2013
Matèries:
Sequence Notes
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3581023/
https://ncbi.nlm.nih.gov/pubmed/23045961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2011.0334
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars